Experimental Group 1: Color Correcting Lenses for Color Blindness, Red

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
University of the Incarnate Word Rosenberg School of Optometry, San Antonio, TX
Color Blindness, Red+4 More
Experimental Group 1: Color Correcting Lenses - Device
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial shows that color-correcting lenses improve color vision in people with deficiencies. The first experimental group is using color correcting lenses to treat color blindness that is specifically red-based. This treatment method has been previously approved by the FDA for a different condition.

Eligible Conditions

  • Color Blindness, Red
  • Color Blindness, Green
  • Achromatopsia
  • Color Blindness

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Color Blindness, Red

Study Objectives

6 Primary · 0 Secondary · Reporting Duration: 2 Weeks

2 WeekS
Cone Contrast Test
2 Weeks
Color Identification Test
Color Matching
Cone Contrast Naming Test
Letter Chart Testing
Visual Electrodiagnostic Testing

Trial Safety

Safety Progress

1 of 3

Other trials for Color Blindness, Red

Trial Design

5 Treatment Groups

Control Group: Subjects with Normal Color Vision
1 of 5
Color Vision Deficient with Color Correcting Lenses
1 of 5
Crossover: Placebo to Experimental
1 of 5
Crossover: Experimental to Placebo
1 of 5
Color Vision Deficient with Placebo Lenses
1 of 5
Active Control
Experimental Treatment
Non-Treatment Group

35 Total Participants · 5 Treatment Groups

Primary Treatment: Experimental Group 1: Color Correcting Lenses · Has Placebo Group · N/A

Color Vision Deficient with Color Correcting Lenses
Device
Experimental Group · 1 Intervention: Experimental Group 1: Color Correcting Lenses · Intervention Types: Device
Crossover: Placebo to Experimental
Device
Experimental Group · 1 Intervention: Placebo Group 1 Crosses over to become Experimental Group 2: Color Correcting Lenses · Intervention Types: Device
Control Group: Subjects with Normal Color Vision
Device
ActiveComparator Group · 1 Intervention: Color Correcting Lenses in Subjects with Normal Color Vision · Intervention Types: Device
Crossover: Experimental to Placebo
Device
PlaceboComparator Group · 1 Intervention: Experimental Group 1 Crosses over to become Placebo Group 2: Placebo Lenses · Intervention Types: Device
Color Vision Deficient with Placebo Lenses
Device
PlaceboComparator Group · 1 Intervention: Placebo Group 1: Placebo Lenses · Intervention Types: Device

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 2 weeks
Closest Location: University of the Incarnate Word Rosenberg School of Optometry · San Antonio, TX
Photo of San Antonio 1Photo of San Antonio 2Photo of San Antonio 3
2018First Recorded Clinical Trial
1 TrialsResearching Color Blindness, Red
1 CompletedClinical Trials

Who is running the clinical trial?

University of the Incarnate WordLead Sponsor
14 Previous Clinical Trials
3,464 Total Patients Enrolled
National Eye Institute (NEI)NIH
514 Previous Clinical Trials
1,074,040 Total Patients Enrolled
Jeffrey RabinPrincipal InvestigatorC

Eligibility Criteria

Age 18+ · All Participants · 4 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have a hereditary color vision deficiency (CVDs).
You have a VA of 20/30 or better in each eye.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References